EA
CNCE

Emerald Acquisition’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Emerald Acquisition’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$686K Sell
67,881
-20,349
-23% -$222K ﹤0.01% 2307
2016
Q2 		$991K Buy
+88,230
New +$1.12M ﹤0.01% 2179

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Acquisition's CNCE Position: Q3 2016 in Review

Emerald Acquisition reduced its Concert Pharmaceuticals, Inc. (CNCE) stake by 23% in Q3 2016, selling an estimated $222K and leaving 67,881 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

Emerald Acquisition first reported a position in CNCE in Q2 2016 and has held it in 2 quarters since. The position peaked at $991K in Q2 2016. 94 funds tracked by Wall St. Rank hold CNCE as of Q3 2016.

  • Emerald Acquisition held 67,881 shares of Concert Pharmaceuticals, Inc. worth $686K as of Q3 2016.
  • Emerald Acquisition sold 20,349 Concert Pharmaceuticals, Inc. shares in Q3 2016, an estimated $222K.
  • Concert Pharmaceuticals, Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2307 holding.
  • Emerald Acquisition first reported a position in Concert Pharmaceuticals, Inc. in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Concert Pharmaceuticals, Inc. position peaked at $991K in Q2 2016.
  • 94 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.